Jon W Fjalstad1, Hans J Stensvold, Håkon Bergseng, Gunnar S Simonsen, Bodil Salvesen, Arild E Rønnestad, Claus Klingenberg. 1. From the *Paediatric Research Group, Faculty of Health Sciences, University of Tromsø-Arctic University of Norway, Tromsø, Norway; †Women and Children's Clinic, Neonatal Intensive Care Unit, Oslo University Hospital, Oslo, Norway; ‡Department of Pediatrics, St. Olavs Hospital, Trondheim, Norway; §Department of Laboratory Medicine, Children's and Women's Health, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway; ¶Department of Microbiology and Infection Control, University Hospital North Norway, Tromsø, Norway; ‖Research Group for Host-Microbe Interaction, Institute of Medical Biology, Faculty of Health Sciences, University of Tromsø-Arctic University of Norway, Tromsø, Norway; **Department of Paediatrics, Haukeland University Hospital, Bergen, Norway; and ††Department of Paediatrics and Adolescence Medicine, University Hospital North Norway, Tromsø, Norway.
Abstract
BACKGROUND: Sepsis is a leading cause of neonatal morbidity and mortality. Clinical suspicion may lead to overuse of antibiotics. The objective of this study was to assess the epidemiology of early-onset sepsis (EOS) and antibiotic exposure during the first week of life in Norwegian term infants. METHODS: This is a nationwide population-based study from the Norwegian Neonatal Network. During the 3-year study period (2009-2011), 20 of Norway's 21 neonatal units prospectively collected data. Among 168,877 live-born (LB) term infants born during the study period, 10,175 (6.0%) infants were hospitalized in the first week of life and included in the study. RESULTS: There were 91 cases of culture-confirmed EOS (0.54 per 1000 LB) and 1447 cases classified as culture-negative EOS (8.57 per 1000 LB). The majority of culture-confirmed EOS cases were caused by Gram-positives (83/91; 91%), most commonly group B streptococci (0.31 per 1000 LB). Intravenous antibiotics were administered to 3964 infants; 39% of all admissions and 2.3% of all LB term infants. Empiric therapy consisted of an aminoglycoside and either benzylpenicillin or ampicillin in 95% of the cases. The median (interquartile range) treatment duration was 8 (7-10) days for culture-confirmed EOS and 6 (5-7) days for culture-negative EOS. There was 1 EOS-attributable death (group B streptococcal EOS) during the study period. CONCLUSIONS: In this registry-based study, the incidence of culture-confirmed EOS was in line with previous international reports and the mortality was very low. A large proportion of infants without infection were treated with antibiotics. Measures should be taken to spare neonates unnecessary antibiotic treatment.
BACKGROUND:Sepsis is a leading cause of neonatal morbidity and mortality. Clinical suspicion may lead to overuse of antibiotics. The objective of this study was to assess the epidemiology of early-onset sepsis (EOS) and antibiotic exposure during the first week of life in Norwegian term infants. METHODS: This is a nationwide population-based study from the Norwegian Neonatal Network. During the 3-year study period (2009-2011), 20 of Norway's 21 neonatal units prospectively collected data. Among 168,877 live-born (LB) term infants born during the study period, 10,175 (6.0%) infants were hospitalized in the first week of life and included in the study. RESULTS: There were 91 cases of culture-confirmed EOS (0.54 per 1000 LB) and 1447 cases classified as culture-negative EOS (8.57 per 1000 LB). The majority of culture-confirmed EOS cases were caused by Gram-positives (83/91; 91%), most commonly group B streptococci (0.31 per 1000 LB). Intravenous antibiotics were administered to 3964 infants; 39% of all admissions and 2.3% of all LB term infants. Empiric therapy consisted of an aminoglycoside and either benzylpenicillin or ampicillin in 95% of the cases. The median (interquartile range) treatment duration was 8 (7-10) days for culture-confirmed EOS and 6 (5-7) days for culture-negative EOS. There was 1 EOS-attributable death (group B streptococcal EOS) during the study period. CONCLUSIONS: In this registry-based study, the incidence of culture-confirmed EOS was in line with previous international reports and the mortality was very low. A large proportion of infants without infection were treated with antibiotics. Measures should be taken to spare neonates unnecessary antibiotic treatment.
Authors: Ming Ying Gan; Wen Li Lee; Bei Jun Yap; Shu Ting Tammie Seethor; Rachel G Greenberg; Jen Heng Pek; Bobby Tan; Christoph Paul Vincent Hornik; Jan Hau Lee; Shu-Ling Chong Journal: Front Pediatr Date: 2022-06-03 Impact factor: 3.569
Authors: Helgi Padari; Tuuli Metsvaht; Eva Germovsek; Charlotte I Barker; Karin Kipper; Koit Herodes; Joseph F Standing; Kersti Oselin; Tõnis Tasa; Hiie Soeorg; Irja Lutsar Journal: Antimicrob Agents Chemother Date: 2018-04-26 Impact factor: 5.191
Authors: Alexa Dierig; Christoph Berger; Philipp K A Agyeman; Sara Bernhard-Stirnemann; Eric Giannoni; Martin Stocker; Klara M Posfay-Barbe; Anita Niederer-Loher; Christian R Kahlert; Alex Donas; Paul Hasters; Christa Relly; Thomas Riedel; Christoph Aebi; Luregn J Schlapbach; Ulrich Heininger Journal: Front Pediatr Date: 2018-08-08 Impact factor: 3.418
Authors: Lola Madrid; Anna C Seale; Maya Kohli-Lynch; Karen M Edmond; Joy E Lawn; Paul T Heath; Shabir A Madhi; Carol J Baker; Linda Bartlett; Clare Cutland; Michael G Gravett; Margaret Ip; Kirsty Le Doare; Craig E Rubens; Samir K Saha; Ajoke Sobanjo-Ter Meulen; Johan Vekemans; Stephanie Schrag Journal: Clin Infect Dis Date: 2017-11-06 Impact factor: 20.999
Authors: Claus Klingenberg; René F Kornelisse; Giuseppe Buonocore; Rolf F Maier; Martin Stocker Journal: Front Pediatr Date: 2018-10-09 Impact factor: 3.418